Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Introduction Uterine fibroids (UFs) are the most common benign tumor arising from myometrium of reproductive age women, with significant financial burden estimated in hundreds of billions of dollars. Unfortunately, there are limitations in available long-term treatment options. Thus, there is a large unmet need in the UF space for noninvasive therapeutics. Areas covered Authors reviewed the literature available for elagolix; an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) antagonist recently approved by the US Food and Drug Administration (FDA) in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with UFs in premenopausal women. Expert opinion The utility of new-generation oral GnRH-antagonists, such as elagolix, relugolix and linzagolix, is offering a new potential opportunity for the future therapy of UFs: elagolix has been the most studied drug of this class for treating benign gynecological diseases, including endometriosis and UFs, for which it has been US FDA-approved in 2018 and 2020, respectively.

Automated summary

Uterine fibroids (UFs) are common benign tumors in women of reproductive age, with limitations in current treatment options, creating a need for noninvasive therapeutics. Elagolix, a new-generation oral GnRH antagonist, shows potential for future UF therapy, having been FDA-approved for treating benign gynecological diseases.